Prospective monitoring of donor-specific anti-HLA antibodies after intestine/multivisceral transplantation: Significance of De novo antibodies

Transplantation

Volumn 99, Issue 8, 2015, Pages e49-e56

  Kubal, Chandrashekhar ^a   Mangus, Richard ^a   Saxena, Romil ^a   Lobashevsky, Andrew ^a   Higgins, Nancy ^a   Fridell, Jonathan ^a   Tector, A Joseph ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BORTEZOMIB; DACLIZUMAB; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PEPTIDE FRAGMENT;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CHILD; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTESTINE TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVISCERAL TRANSPLANTATION; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STAINING; TRANSPLANTATION; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; DRUG COMBINATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INTESTINE; METABOLISM; MIDDLE AGED; ORGAN TRANSPLANTATION; PRESCHOOL CHILD; RISK FACTOR; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COMPLEMENT C4B; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTESTINES; ISOANTIBODIES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940697207     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000614     Document Type: Article

References (33)

1. Farmer DG, McDiarmid SV, Yersiz H, et al. Outcome after intestinal transplantation: results from one center's 9-year experience; discussion 1031-2. Arch Surg. 2001;136:1027.
2. Gerlach UA, Lachmann N, Sawitzki B, et al. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. Transpl Int. 2013;27:280.
3. Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant. 2012;12:3047.
4. Tsai HL, Island ER, Chang JW, et al. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation. 2011;92:709.
5. Mangus RS, Tector AJ, Fridell JA, Kazimi M, Hollinger E, Vianna RM. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in intestinal and multivisceral transplantation. Transplantation. 2008;86:298.
6. Vianna RM, Mangus RS, Fridell JA, Kazimi M, Hollinger E, Tector J. Initiation of an intestinal transplant program: the Indiana experience. Transplantation. 2008;85:1784.
7. Lobashevsky AL SR, Shoaf J, et al. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant. 2000;14:533.
8. Kubal CA, Mangus RS, Vianna RM, et al. Impact of positive flow cytometry crossmatch on outcomes of intestinal/multivisceral transplantation: role anti-IL-2 receptor antibody. Transplantation. 2013;95:1160.
9. Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation. 2008;85:1290.
10. Vianna R, Kubal C, Mangus R, Fridell J, Tector J. Intestinal and multivisceral transplantation at Indiana University: 6 years' experience with 100 cases. Clin Transpl. 2009:219.
11. Ruiz P, Bagni A, Brown R, et al. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc. 2004;36:335.
12. Parizhskaya M, Redondo C, Demetris A, et al. Chronic rejection of small bowel grafts: pediatric and adult study of risk factors and morphologic progression. Pediatr Dev Pathol. 2003;6:240.
13. Swanson BJ, Talmon GA, Wisecarver JW, Grant WJ, Radio SJ. Histologic analysis of chronic rejection in small bowel transplantation: mucosal and vascular alterations. Transplantation. 2013;95:378.
14. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation. 2000;69:1370.
15. Mulley WR, Kanellis J. Understanding crossmatch testing in organ transplantation: a case-based guide for the general nephrologist. Nephrology (Carlton). 2011;16:125.
16. Graff RJ, Buchanan PM, Dzebisashvili N, et al. The clinical importance of flow cytometry crossmatch in the context of CDC crossmatch results. Transplant Proc. 2010;42:3471.
17. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med. 2006;130:1489.
18. de Serre NP, Canioni D, Lacaille F, et al. Evaluation of c4d deposition and circulating antibody in small bowel transplantation. Am J Transplant. 2008;8:1290.
19. Ruiz P. Updates on acute and chronic rejection in small bowel and multivisceral allografts. Curr Opin Organ Transplant. 2014;19:293.
20. Gerlach UA, Lachmann N, Sawitzki B, et al. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. Transpl Int. 2013;27:280.
21. Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009;87:1325.
22. Yin H, Wan H, Hu XP, et al. Rituximab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl). 2011;124:1928.
23. Kubal CA, Mangus RS, Saxena R, et al. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation. 2014;97:56.
24. Lobashevsky A, Rosner K, Goggins W, Higgins N. Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol. 2010;23:81.
25. Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol. 2009;70:600.
26. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157.
27. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant. 2009;9:2561.
28. Bachelet T, Couzi L, Lepreux S, et al. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. Am J Transplant. 2013;13:2855.
29. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis. 1992;12:51.
30. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol. 2012;26:62.
31. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg. 2001;234:404; discussion 16-7.
32. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998;186:512; discussion 25-7.
33. Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int. 2009;22:96.